CD274 and head and neck squamous cell carcinoma: To date, the U.S. Food and Drug Administration (FDA) has approved three PD-1 inhibitors (nivolumab, pembrolizumab, and cemiplimab) and three PD-L1 inhibitors (atezolimumab, durvalumab and avelumab) for the treatment of solid tumors in different clinical settings, including non-small-cell lung cancer (NSCLC), melanoma, urothelial carcinoma, head and neck squamous cell carcinoma (HNSCC) and merkel cell carcinoma (MCC).